Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term GI safety of aliskiren versus ramipril in essential hypertension
2007-005256-16Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren in essential hypertension (2 arms), sponsored by Novartis. Primary endpoints: Occurrence of an abnormal colonoscopy finding and Composite colonic pathology endpoint. Started Dec 2007; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2007-005256-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005256-16.